Compare MTEN & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTEN | ONCO |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.3M |
| IPO Year | 2024 | 2022 |
| Metric | MTEN | ONCO |
|---|---|---|
| Price | $1.77 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 707.6K | 439.8K |
| Earning Date | 10-01-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,735,337.00 | $1,223,751.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.63 | N/A |
| 52 Week Low | $1.57 | $1.06 |
| 52 Week High | $5,206.00 | $49.89 |
| Indicator | MTEN | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 54.97 | 38.02 |
| Support Level | $1.61 | $1.15 |
| Resistance Level | $1.94 | $1.86 |
| Average True Range (ATR) | 0.40 | 0.18 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 6.40 | 2.81 |
Mingteng International Corp Inc operates as an automotive mold developer and supplier in China. It provides an extensive product lineup including casting molds for turbocharger systems, braking systems, steering and differential systems, and other automotive system parts. Besides, it also produces molds for new energy electric vehicle motor drive systems, battery pack systems, and engineering hydraulic components, which are widely used in the automobile, construction machinery, and other manufacturing industries.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.